Results 171 to 180 of about 4,767 (196)
Oncolytic Vaccinia Virus: A Theranostic Agent for Cancer
Future Virology, 2010 Vaccinia virus (VACV) is arguably the most successful live biotherapeutic agent because of its critical role in the eradication of smallpox, one of the most deadly diseases in human history. VACV has been exploited as an oncolytic therapeutic agent for cancer since 1922.
Nanhai G Chen, Aladar A Szalay
openaire +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Single-particle characterization of oncolytic vaccinia virus by flow virometry
Vaccine, 2016Vaccinia virus (VV) is an oncolytic virus that is currently being evaluated as a promising cancer vaccine in several phase I, II and III clinical trials. Although several quality control tests are performed on each new batch of virus, these do not routinely include a systematic characterization of virus particle homogeneity, or relate the infectious ...
Vera A Tang +2 more
exaly +3 more sources
Engineering oncolytic vaccinia virus to redirect macrophages to tumor cells
ADVANCES IN CELL AND GENE THERAPY, 2020 Oncolytic virotherapy has been tested in numerous early phase clinical studies. However, the antitumor activity of oncolytic viruses thus far has been limited. Numerous strategies are being explored to enhance their antitumor activity by activating the adaptive arm of the immune system.
Felicia Cao +12 more
openaire +4 more sources
Future directions for the field of oncolytic virotherapy: a perspective on the use of vaccinia virus
Expert Opinion on Biological Therapy, 2004Oncolytic virotherapy is an emerging biotherapeutic platform based on genetic engineering of viruses capable of selectively infecting and replicating within cancer cells. Such viruses have been found to be both safe and to produce antitumour effects in a number of Phase I and II clinical trials.
Steve H Thorne
exaly +3 more sources
Recombinant strains of oncolytic vaccinia virus for cancer immunotherapy
Биохимия, 2023Cancer virotherapy is an alternative therapeutic approach based on the viruses that selectively infect and kill tumor cells. Vaccinia virus (VV) is a member of the Poxviridae family of enveloped viruses with a large linear double-stranded DNA genome. The proven safety of VV strains as well as considerable transgene capacity of the viral genome, make VV
Yasmin, Shakiba +8 more
openaire +2 more sources
Oncolytic vaccinia virus for the treatment of cancer
Expert Opinion on Biological Therapy, 2011Gene therapy offers promising approaches for the development of anticancer agents with new modes of action. Among gene therapy vectors, vaccinia virus has emerged as an attractive agent especially when used as an oncolytic virus.This review describes the use of vaccinia virus in cancer therapy as a gene therapy vector, as an oncolytic virus and in the ...
Kilian, Guse +2 more
openaire +3 more sources
The Combination of Carboxylesterase-Expressing Oncolytic Vaccinia Virus and Irinotecan
, 2013 This project combines oncolytic Vaccinia virus (VV) with irinotecan (CPT-11) for the treatment of cancer. VV can infect, replicate in and destroy cancer cells, yet leave healthy cells relatively unaffected. CPT-11 is a chemotherapeutic of which ~5% is converted to the more active chemotherapeutic SN-38 by endogenous carboxylesterase (CE) enzymes. SN-38
Becker, Michelle Caitlin
openaire +3 more sources
Oncolytic Vaccinia Virus Gene Therapy for HNSCC
Otolaryngology–Head and Neck Surgery, 2008ProblemOncolytic viral therapy a promising new strategy for the treatment of cancer and an oncolytic adenovirus was first licensed for head and neck squamous cell carcinoma (HNSCC). However, the outcomes of clinical trials with viral monotherapy have been disappointing. Oncolytic vaccinia virus represents an attractive alternative as its replication is
James Russell Tysome +3 more
openaire +1 more source
Progress in gene therapy using oncolytic vaccinia virus as vectors
Journal of Cancer Research and Clinical Oncology, 2018Vaccinia virus was widely used in the World Health Organization's smallpox eradication campaign and is currently a promising vector for gene therapy owing to its unique characteristics. Vaccinia virus can selectively replicate and propagate productively in tumor cells, resulting in oncolysis.
Xue Yang +3 more
openaire +2 more sources
Vaccinia virus and oncolytic virotherapy of cancer.
Current opinion in molecular therapeutics, 2005Vaccinia viruses possess many of the key attributes necessary for an ideal viral backbone for use in oncolytic virotherapy. These include a short lifecycle, with rapid cell-to-cell spread. strong lytic ability, a large cloning capacity and well-defined molecular biology.
Stephen H, Thorne +2 more
openaire +1 more source